The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$92,933 Vol.
$92,933 Vol.
31 déc. 2026
$92,933 Vol.
$92,933 Vol.
31 déc. 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Marché ouvert : May 4, 2026, 10:39 AM ET
Volume
$92,933Date de fin
31 déc. 2026Marché ouvert
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$92,933Date de fin
31 déc. 2026Marché ouvert
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes